Literature DB >> 19001215

Temperature instability of ReNu With MoistureLoc: a new theory to explain the worldwide Fusarium keratitis epidemic of 2004-2006.

John D Bullock1, Ronald E Warwar, B Laurel Elder, William I Northern.   

Abstract

OBJECTIVE: To investigate the effect of storage temperature on the ability of contact lens solutions to inhibit growth of Fusarium species. A 2006 Food and Drug Administration inspection of Bausch & Lomb's Greenville, South Carolina, manufacturing site indicated that Bausch & Lomb failed to regulate storage and transport temperatures of their products.
METHODS: Six contact lens solutions were studied: ReNu with MoistureLoc, ReNu MultiPlus, COMPLETE Moistureplus, AQuify, Clear Care, and OPTI-FREE RepleniSH. Two bottles of each solution were separately stored at room temperature and 60 degrees C for 4 weeks, serially diluted, and then tested for their ability to inhibit growth of 11 Fusarium isolates (7 of which were associated with the keratitis epidemic).
RESULTS: ReNu with MoistureLoc demonstrated the greatest decline in efficacy after 60 degrees C storage. Clear Care and ReNu MultiPlus performed the best. Regarding the keratitis epidemic isolates only, the ReNu with MoistureLoc bottle stored at room temperature allowed growth in 27 of 84 combinations vs 67 of 84 combinations with the 60 degrees C-stored bottle.
CONCLUSIONS: When exposed to prolonged temperature elevation, ReNu with MoistureLoc loses its in vitro fungistatic activity to a much greater extent than other products. Improper temperature control of ReNu with MoistureLoc may have contributed to the Fusarium keratitis epidemic of 2004-2006.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001215     DOI: 10.1001/archopht.126.11.1493

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

Review 1.  Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis.

Authors:  F Stapleton; N Carnt
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

2.  Recent outbreaks of atypical contact lens-related keratitis: what have we learned?

Authors:  Elmer Y Tu; Charlotte E Joslin
Journal:  Am J Ophthalmol       Date:  2010-11       Impact factor: 5.258

3.  Root cause analysis of the fusarium keratitis epidemic of 2004-2006 and prescriptions for preventing future epidemics.

Authors:  John D Bullock
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

4.  Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.

Authors:  N Venkatesh Prajna; Tiruvengada Krishnan; Revathi Rajaraman; Sushila Patel; Ranjeet Shah; Muthiah Srinivasan; Lumbini Devi; Manoranjan Das; Kathryn J Ray; Kieran S O'Brien; Catherine E Oldenburg; Stephen D McLeod; Michael E Zegans; Nisha R Acharya; Thomas M Lietman; Jennifer Rose-Nussbaumer
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

Review 5.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

6.  Contact lens solution-associated Acanthamoeba and Fusarium keratitis.

Authors:  John D Bullock; Ronald E Warwar
Journal:  Emerg Infect Dis       Date:  2010-09       Impact factor: 6.883

7.  American Academy of Optometry Microbial Keratitis Think Tank.

Authors:  Loretta B Szczotka-Flynn; Joseph P Shovlin; Cristina M Schnider; Barbara E Caffery; Eduardo C Alfonso; Nicole A Carnt; Robin L Chalmers; Sarah Collier; Deborah S Jacobs; Charlotte E Joslin; Abby R Kroken; Carol Lakkis; Eric Pearlman; Oliver D Schein; Fiona Stapleton; Elmer Tu; Mark D P Willcox
Journal:  Optom Vis Sci       Date:  2021-03-01       Impact factor: 2.106

8.  The use of preservatives in dry eye drops.

Authors:  Karen Walsh; Lyndon Jones
Journal:  Clin Ophthalmol       Date:  2019-08-01

9.  In-vitro analysis of the microbicidal activity of 6 contact lens care solutions.

Authors:  Claudia Hildebrandt; Daniela Wagner; Thomas Kohlmann; Axel Kramer
Journal:  BMC Infect Dis       Date:  2012-10-03       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.